Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GAUTAM B KARETI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1134326697
CMS profile
1136027
Location
LANCASTER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,806.85

116 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,915.93 112
Travel and Lodging $829.42 3
Education $61.50 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GAUTAM B KARETI

NPI 1134326697 · CMS profile ID 1136027

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

LANCASTER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134326697?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GAUTAM B KARETI, NPI 1134326697, CMS profile ID 1136027. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134326697?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GAUTAM B KARETI, NPI 1134326697, CMS profile ID 1136027. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134326697?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GAUTAM B KARETI, NPI 1134326697, CMS profile ID 1136027, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1134326697?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

116 matching records · $3,806.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 116 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–116 of 116.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $6.1003/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954908857 CMS
ABBVIE INC. $7.6703/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893013105 CMS
AstraZeneca Pharmaceuticals LP $11.9403/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914677843 CMS
ABBVIE INC. $20.9603/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893013101 CMS
Biogen, Inc. $97.6903/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923412327 CMS
LivaNova USA, Inc. $26.2703/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942195699 CMS
Celgene Corporation $14.5502/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932666251 CMS
LivaNova USA, Inc. $62.3802/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942195673 CMS
LivaNova USA, Inc. $133.5702/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942195677 CMS
LivaNova USA, Inc. $172.4702/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942195827 CMS
LivaNova USA, Inc. $214.9502/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942195831 CMS
LivaNova USA, Inc. $442.0002/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942195835 CMS
LivaNova USA, Inc. $185.1402/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942195839 CMS
Biogen, Inc. $1.0401/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923387153 CMS
Biogen, Inc. $20.8301/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923436401 CMS
Celgene Corporation $13.0601/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932666249 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $761.06 45
PY2020 $227.12 12
PY2021 $399.62 13
PY2022 $3,806.85 116
PY2023 $1,338.02 71
PY2024 $1,304.26 54
PY2025 $1,750.60 61

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $223,323.79 28
PY2024 Principal investigator $73,850.00 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merz Pharmaceuticals, LLC $1,100.00 12/10/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647217
Principal investigator 1 GENZYME CORPORATION $24,924.24 11/17/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079831
Principal investigator 1 GENZYME CORPORATION $33,518.34 11/17/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079835
Principal investigator 1 Merz Pharmaceuticals, LLC $14,000.00 11/14/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647219
Principal investigator 1 Merz Pharmaceuticals, LLC $14,000.00 11/07/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647227
Principal investigator 1 Merz Pharmaceuticals, LLC $2,250.00 11/03/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647233
Principal investigator 1 Merz Pharmaceuticals, LLC $1,100.00 10/29/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647221
Principal investigator 1 Merz Pharmaceuticals, LLC $9,500.00 10/29/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647223
Principal investigator 1 Merz Pharmaceuticals, LLC $2,300.00 10/29/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647225
Principal investigator 1 Merz Pharmaceuticals, LLC $1,800.00 10/29/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647229
Principal investigator 1 Merz Pharmaceuticals, LLC $2,250.00 10/29/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647231
Principal investigator 1 GENZYME CORPORATION $1,400.00 10/14/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079827
Principal investigator 1 GENZYME CORPORATION $8,539.83 09/22/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079823
Principal investigator 1 Merz Pharmaceuticals, LLC $1,800.00 08/15/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647207
Principal investigator 1 Merz Pharmaceuticals, LLC $1,100.00 08/15/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647209
Principal investigator 1 Merz Pharmaceuticals, LLC $2,300.00 08/15/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647211
Principal investigator 1 Merz Pharmaceuticals, LLC $1,100.00 08/15/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647213
Principal investigator 1 Merz Pharmaceuticals, LLC $9,500.00 08/15/2025 Non-covered Recipient Entity
CHEMIDOX ADVANCE CLINICAL TRIALS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647215
Principal investigator 1 GENZYME CORPORATION $5,164.29 08/04/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079815
Principal investigator 1 GENZYME CORPORATION $6,751.08 08/04/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079819
Principal investigator 1 GENZYME CORPORATION $7,828.38 07/02/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079810
Principal investigator 1 GENZYME CORPORATION $1,980.00 06/16/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079802
Principal investigator 1 ABBVIE INC. $2,008.72 06/05/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202490579
Principal investigator 1 Novartis Pharmaceuticals Corporation $30,298.00 05/22/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190312135
Principal investigator 1 GENZYME CORPORATION $6,613.65 05/19/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079806
Principal investigator 1 GENZYME CORPORATION $26,767.26 05/12/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079797
Principal investigator 1 GENZYME CORPORATION $2,000.00 04/02/2025 Non-covered Recipient Entity
Chemidox Advance Clinical Trials Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226079794
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,430.00 01/31/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190313109